Investors sentiment increased to 1.35 in Q2 2019. Its up 0.14, from 1.21 in 2019Q1. It increased, as 8 investors sold Achillion Pharmaceuticals, Inc. shares while 29 reduced holdings. 23 funds opened positions while 27 raised stakes. 96.90 million shares or 7.35% less from 104.58 million shares in 2019Q1 were reported.
Jacobs Levy Equity Inc has invested 0% in Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN). Citadel Advsrs Lc holds 2.12 million shares. Aperio Gp Ltd Company reported 0% in Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN). Marshall Wace Llp accumulated 0% or 37,495 shares. Meeder Asset Management has invested 0% of its portfolio in Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN). Daiwa Grp Inc stated it has 762 shares or 0% of all its holdings. Jnba Fincl Advsr has 100 shares. Vanguard Gp owns 0% invested in Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) for 12.26 million shares. Amalgamated Bancshares invested in 19,906 shares. Paloma Prns Mngmt has 0% invested in Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN). Ny State Common Retirement Fund owns 129,700 shares for 0% of their portfolio. Legal And General Group Public Ltd Co has 25,275 shares. Cwm Limited Liability Com holds 0% of its portfolio in Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) for 75 shares. Dekabank Deutsche Girozentrale owns 108,600 shares for 0% of their portfolio. Sector Pension Invest Board holds 0.01% or 378,000 shares.
Achillion Pharmaceuticals (NASDAQ:ACHN) Stock Upgrade
Shares of Achillion Pharmaceuticals (NASDAQ:ACHN) were raised to a solid Sell rating by analysts working for BidaskScore. ACHN’s previous rating has been discontinued by the firm.
The stock decreased 0.64% or $0.04 during the last trading session, reaching $6.17. About 946,564 shares traded. Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) has risen 66.42% since December 5, 2018 and is uptrending. It has outperformed by 66.42% the S&P500.
Analysts await Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) to report earnings on March, 5. They expect $-0.16 EPS, down 33.33 % or $0.04 from last year’s $-0.12 per share. After $-0.14 actual EPS reported by Achillion Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts 14.29 % negative EPS growth.
Achillion Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes small molecule drug therapies for infectious diseases and immune system disorders in the United States and internationally. The company has market cap of $864.37 million. The Company’s drug candidates for treating chronic hepatitis C virus infection comprise Odalasvir, a NS5A inhibitor, which has completed Phase IIa clinical trials; ACH-3422, a NS5B nucleotide polymerase inhibitor; and Sovaprevir, a NS3 protease inhibitor that has completed Phase II clinical trial. It currently has negative earnings. The firm is also developing ACH-4471, a complement factor D inhibitor, which is in Phase I clinical trial to treat patients with paroxysmal nocturnal hemoglobinuria and C3G, a disease resulting from alternative pathway over-activation; and other factor D inhibitors.
More notable recent Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) news were published by: Benzinga.com which released: “35 Stocks Moving In Monday’s Pre-Market Session – Benzinga” on July 22, 2019, also Nasdaq.com with their article: “Pharma Sector Tops in October: Best ETFs & Stocks – Nasdaq” published on November 08, 2019, Fool.com published: “Why Achillion Pharmaceuticals, Tech Data, and First Majestic Silver Jumped Today – The Motley Fool” on October 16, 2019. More interesting news about Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) were released by: Seekingalpha.com and their article: “EMA grants PRIME designation to Achillion’s danicopan – Seeking Alpha” published on November 19, 2019 as well as Investorplace.com‘s news article titled: “This $2.7 Billion Deal Is a Shot Across the Bow for Big Pharma – Investorplace.com” with publication date: November 08, 2019.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.